Compare Abeona Therapeutics Inc (ABEO) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SYSCO Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while SYSCO Corporation trades at $83.28 (market cap $40.46B). The key difference: SYSCO Corporation is far larger — about 108.4× Abeona Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.6% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SYY | |
|---|---|---|
Market Cap | $373.32M | $40.46B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $91.16 |
52-Week Low | $4.17 | $69.30 |
Enterprise Value | $228.22M | $53.94B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Sysco (SYY) trades at $84.62, down 0.25% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains steady revenue growth, reaching $81.37B in 2025. Analyst consensus is a Buy with a $83.67 price target, supported by recent corporate developments including AI awards and World Cup supply chain preparations.
Outlook remains positive due to strong institutional support and strategic initiatives, though risks include margin pressure from rising costs and high debt levels. The stock's valuation metrics like P/E of 23.4 and P/S of 0.49 suggest reasonable pricing, but investors should monitor execution on future earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
